Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
China is a country with a large incidence of esophageal cancer. The prevalence and mortality
rate of esophageal cancer in China ranks fifth in the world. However, due to China's huge
population base, new patients with esophageal cancer and deaths account for about 55% of the
world. This study aimed to explore the efficacy and safety of Camrelizumab Combined With
Concurrent Radiotherapy and Chemotherapy for Treatment of Patients With Local Recurrence of
Esophageal Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Henan University of Science and Technology